A research by Ohio State University has shown an association between breast cancer survivor’s use of Proton Pump Inhibitors (PPI) and reports of problems with concentration and memory. On an average, the problems reported by PPI users were between 20 to 29 percent more severe than issues reported by non-PPI users.

After eliminating variety of other factors that could affect memory and concentration, the researchers arrived at the conclusion that PPI users had more severe concentration and memory problems as well as low quality of life related to impaired cognition.

PPIs are over the counter medicines and are considered safe so there has not been many long-term trials, especially looking into cognitive outcomes. But researchers thought there could be a cognitive effect from taking PPIs, particularly in this population, because breast cancer survivors are already at risk for cognitive decline. The study that followed established the link between PPIs and impairment of memory and concentration in patients with breast cancer.